SGLT-2抑制剂引起糖尿病患者急性肾损伤的机制  

Mechanisms of acute renal injury caused by SGLT-2 inhibitor in patients with diabetes mellitus

作　　者：巩艳 贺巧艳[1] 杨小娟[1] Gong Yan;He Qiao-yan;Yang Xiao-juan(Department of Nephrology,Affiliated Hospital,Yan’an University,Yan’an 716000,China)

机构地区：[1]延安大学附属医院肾内科,延安716000

出　　处：《临床肾脏病杂志》2021年第12期1044-1048,共5页Journal Of Clinical Nephrology

摘　　要：钠-葡萄糖共转运蛋白-2(sodium-glucose cotransporter-2,SGLT-2)抑制剂是一种2型糖尿病(diabetes mellitus type 2,T2DM)降糖药物,大量的临床试验表明它能降低T2DM患者的心血管病死率,但越来越多的证据表明SGLT-2抑制剂的使用可能与发生急性肾损伤(acute kidney injury, AKI)的风险有关,本文就SGLT-2抑制剂引起AKI的机制做一综述,对相关机制的了解可能有助于识别有发生AKI风险的个体。Sodium-glucose cotransporter-2 inhibitor is a type 2 diabetes(T2 DM) sugar-lowering agent.Numerous clinical trials have demonstrated that it could lower cardiovascular mortality in type 2 diabetics.As shown by growing evidence, use of SGLT-2 inhibitor was associated with the risk of acute kidney injury(AKI).This review focused upon the mechanisms by which SGLT-2 inhibitor caused AKI and assisted in identifying individuals at a risk of AKI.

关 键 词：SGLT-2抑制剂 急性肾损伤 糖尿病 

分 类 号：R587.2[医药卫生—内分泌] R692.9[医药卫生—内科学]